C4 Therapeutics, Inc. (CCCC)

6.91 +0.04 (+0.58%) At close: 04:00PM EDT

C4 Therapeutics, Inc.

490 Arsenal Way
Suite120
Watertown, MA 02472
United States
617 231 0700
https://www.c4therapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director	971k	N/A	1971
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	39.03k	N/A	1951
Dr. Stewart Fisher	Chief Scientific Officer	657.34k	N/A	1967
Mr. Scott N. Boyle M.B.A., Ph.D.	Chief Business Officer	672.78k	N/A	1978
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Ms. Kendra Adams	Chief Financial Officer	N/A	N/A	N/A
Mr. Mark Mossler	Chief Accounting Officer	N/A	N/A	1973
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary	610.4k	1.06M	1977
Ms. Kelly A. Schick	Chief People Officer	N/A	N/A	1980
Dr. Isabel Chiu Ph.D.	Senior Vice President of Strategic Alliances & Business Development	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Corporate governance

C4 Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.